A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology

• Published in: PloS one Vol. 16; no. 11; p. e0259093
• Main Authors: Athanasiou, Alcibiade, Tennstedt, Pierre, Wittig, Anja, Huber, Ramy, Straub, Oliver, Schiess, Ralph, Steuber, Thomas
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 12.11.2021; Public Library of Science (PLoS)
• Subjects: Adult; Aged; Analysis; Antigens, Neoplasm - blood; Biological markers; Biology and Life Sciences; Biomarkers; Biomarkers, Tumor - blood; Biopsy; Cancer surgery; Diseases; Evaluation; Fibronectin; Galectin-3; Germany - epidemiology; Health risks; Humans; Immunoassay; Immunoassays; Kaplan-Meier Estimate; Male; Matrix metalloproteinase; Medical prognosis; Medicine and Health Sciences; Metalloproteinase; Middle Aged; Modelling; Multivariate analysis; Neoplasm Recurrence, Local - blood; Neoplasm Recurrence, Local - epidemiology; Neoplasm Staging; Pathology; Patients; Prognosis; Prostate cancer; Prostate-Specific Antigen - blood; Prostatectomy; Prostatectomy - methods; Prostatic Neoplasms - blood; Prostatic Neoplasms - epidemiology; Prostatic Neoplasms - pathology; Prostatic Neoplasms - surgery; Proteins; Relapse; Research and Analysis Methods; Retrospective Studies; Risk Assessment; Risk groups; Thrombospondin; Treatment Outcome; Tumor markers; Tumors; Urological surgery; Germany; Switzerland
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0259093

The objective was to determine the prognostic utility of a new biomarker combination in prostate cancer (PCa) patients undergoing Radical Prostatectomy (RP). Serum samples and clinical data of 557 men who underwent RP for PCa with pathological stage (pT) <3 at Martini Clinic (Hamburg, Germany) were used for analysis. Clinical Grade Group and clinical stage was determined using biopsy samples while tumor marker concentrations were measured in serum using immunoassays. The prognostic utility of the proposed marker combination was assessed using Cox proportional hazard regression and Kaplan-Meier analysis. The performance was compared to the Cancer of the Prostate Risk Assessment (CAPRA) score in the overall cohort and in a low-risk patient subset. A multivariable model comprising fibronectin 1, galectin-3-binding protein, lumican, matrix metalloprotease 9, thrombospondin-1 and PSA together with clinical Grade Group (GG) and clinical stage (cT) was created. The proposed model was a significant predictor of biochemical recurrence (BCR) (HR 1.29 per 5 units score, 95%CI 1.20-1.38, p<0.001). The Kaplan-Meier analysis showed that the proposed model had a better prediction for low-risk disease after RP compared to CAPRA (respectively 5.0% vs. 9.1% chance of BCR). In a pre-defined low risk population subset, the risk of BCR using the proposed model was below 5.2% and thus lower when compared to CAPRA = 0-2 (9%), GG<2 (7%) and NCCN = low-risk (6%) subsets. Additionally, the proposed model could significantly (p<0.001) discriminate patients with adverse pathology (AP) events at RP from those without. In conclusion, the proposed model is superior to CAPRA for the prediction of BCR after RP in the overall cohort as well as a in a pre-defined low risk patient population subset. It is also significantly associated with AP at RP.